| Filed On | Filing |
|---|---|
| 06 Apr 2020 |
8-K/A: Departure/Election of Directors or Officers; Compensation
In its Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 12, 2020 (the “Initial Report”) Relmada Therapeutics, Inc. (the “Company”) reported the departure of Dr. Ottavio Vitolo, the Company’s Chief Me... |
| 18 Jul 2019 |
8-K/A: Other Events
This is the adjustment to account for the net proceeds from the financing transactions that occurred on 5/14/19, 6/14/2019, 6/20/19 and 6/28/2019 |
Loading...